Molecular basis of pharmacological therapy in Cushing's disease. - Wikidata - awgldk - TriplyDB

Molecular basis of pharmacological therapy in Cushing's disease.

Molecular basis of pharmacological therapy in Cushing's disease.

http://www.wikidata.org/entity/Q38165863

about

Update on medical treatment for Cushing's disease.Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial Expression of cold-inducible RNA-binding protein (CIRP) in pituitary adenoma and its relationships with tumor recurrence Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review.Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.Ectopic ACTH-secreting pituitary adenomas within the sphenoid sinus.Emerging drugs for Cushing's disease.Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.Diabetes in Cushing Disease.Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.Pituitary-Directed Therapies for Cushing's Disease.New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.

P2860

Q33802284-8A9880BF-46BC-4232-A329-62FF95242165 Q33840655-5CA5CCFF-98D7-473D-ACE9-F517AF544713 Q35596299-3E219728-2F73-4681-B114-8C1BEDCDCBD7 Q36060458-CE8BC621-A5F4-4F76-819A-8918F69E5E56 Q36704499-FF3980AC-A708-4278-B2C3-0E115E5D4DB1 Q38220084-4491B245-0FBF-4C7A-AB30-A4127F7C87C4 Q38505947-2CAFDDAE-837B-45B8-B088-5C340DA3B853 Q38925278-B838B2D9-7965-48F2-8A8D-E8066C4B87D8 Q38968381-3ECACC45-799D-4A31-AB76-BC8F0A04AF53 Q39212408-658AD457-404E-4117-93EE-4A3F36CCDDD1 Q41069104-60D32FF2-A5FB-43B9-8F33-30E9DB3E7CE8 Q54961209-5479E26F-9BC9-425F-93E6-CA24972B1845 Q55249109-5C36D29B-375D-48A8-8AC1-6AA161142132

P2860

Molecular basis of pharmacological therapy in Cushing's disease.

http://www.wikidata.org/entity/Q38165863

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Molecular basis of pharmacological therapy in Cushing's disease.

@en

type

label

Molecular basis of pharmacological therapy in Cushing's disease.

@en

prefLabel

Molecular basis of pharmacological therapy in Cushing's disease.

@en

P1433

Q38165863-38E709FA-EA59-45C1-A6B6-90ACDBF48ECE

P1476

Q38165863-6482E9D4-033E-4426-9270-E1E22A421A99

P2093

Q38165863-59AAC7B3-A7CE-4A23-8902-C23C993825A9

Q38165863-7E9BB3F5-437F-4D1D-9E49-942D974C8079

Q38165863-8F12AC83-AEF6-40D5-810B-A2E378D21316

P2860

Q38165863-0010E367-310F-465D-83BC-D986622EEAA5

Q38165863-01F9E438-B053-46A1-9CFF-D11EB42010A8

Q38165863-04322637-6F7D-4B60-9D7E-F163A5188698

Q38165863-0B4C19BA-100F-4464-AC76-286CBD37E330

Q38165863-0C956297-6218-4A8F-A826-B83FF51E0D2D

Q38165863-0DEACE8B-BE08-44C4-8A35-7319C70247AF

Q38165863-10B1D517-D1B3-40CC-AE4C-62FA22D4DB52

Q38165863-16B20E11-22C1-4F74-841F-06703A81E4F4

Q38165863-1865D7ED-6C87-4F32-944A-598D2BFCE85E

Q38165863-1A212041-1057-42FD-9212-71F9CAC75C7A

P2888

Q38165863-1A8637F8-CC2B-47EA-B649-DF9A021B6D88

P304

Q38165863-2422004A-9E0D-40D1-8E3D-CAD15EB57D79

P31

Q38165863-A1A849B3-CED0-48CE-82B5-EF7D954717C4

P356

Q38165863-0EE32935-87A1-4963-B50D-DB7A96DBA9EC

P433

Q38165863-AFFC8859-3F6D-4170-A566-0793BDCDC864

P478

Q38165863-9684BD58-45D0-48A0-B5E0-B2DAC1736047

P50

Q38165863-15806658-93BD-4C16-A953-BC6735E686B6

Q38165863-879938C7-48D9-49A0-AC71-B072A2EA654A

Q38165863-B088BAE9-2F25-48E1-9A23-95BBE7896B8A

P577

Q38165863-28ECC0D2-BFE2-4498-9C20-E7FF2544E6B7

P5875

Q38165863-29A721FB-1A8D-4598-8803-621BF9836105

P698

Q38165863-A31DD2C1-7AF4-433F-BCF4-C00868D3DA90

P356

S12020-013-0098-5

P1433

P1476

Molecular basis of pharmacological therapy in Cushing's disease.

@en

P2093

Claudia Pivonello

http://www.w3.org/2001/XMLSchema#string

Diego Ferone

http://www.w3.org/2001/XMLSchema#string

Giovanni Vitale

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of Cushing disease: overview and recent findings

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Phase I trial of temozolomide (CCRG 81045: M&B; 39831: NSC 362856)

Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors

Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis

Adjuvant mitotane treatment for adrenocortical carcinoma

Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines

Retinoic acid prevents experimental Cushing syndrome

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Temozolomide-induced inhibition of pituitary adenoma cells.

P2888

s12020-013-0098-5

P304

181-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-013-0098-5

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Maria Chiara Zatelli

Rosario Pivonello

Annamaria Colao

P577

2013-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258856516

http://www.w3.org/2001/XMLSchema#string

P698

24272603

http://www.w3.org/2001/XMLSchema#string